BCL-2 is a protein that helps regulate apoptosis, or programmed cell death, in cells. In certain contexts, this can be beneficial, as it prevents unnecessary cell death and maintains tissue health. However, in the case of aging and certain diseases, an overexpression of BCL-2 can contribute to the survival of damaged or dysfunctional cells. This can lead to issues such as chronic inflammation or cancer, which are detrimental to a dog's overall health and longevity. By inhibiting BCL-2, we can encourage the removal of these unhealthy cells, potentially leading to improved health outcomes for dogs as they age. The concept of using BCL-2 inhibitors in veterinary medicine is still emerging, as research continues to explore how these compounds can be integrated into longevity therapies for dogs. As we learn more about how to promote healthier aging, these inhibitors could become a valuable tool in the veterinary toolkit. They represent a promising area of investigation that aims to improve not just lifespan, but also the quality of life for our canine companions as they navigate their senior years.